APSR2026-215

 
Late-Breaking
Submitted
Poster Presentation
 
AP02-030
P38
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1211877-46904-CHALLENGES IN MANAGING CANDIDA AURIS CANDIDEMIA IN TUBERCULOSIS PATIENTS - A CASE REPORT FROM VIETNAM_434535.pdf
Format: PDF Only
05. Respiratory Infections (non-tuberculous)
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Hue Pham Thi Phuong * National Lung Hospital Tuberculosis and Lung Diseases Hanoi Vietnam
Linh Le Tu - National Lung Hospital Tuberculosis and Lung Diseases Hanoi Vietnam
Long Le Tuan - National Lung Hospital Tuberculosis and Lung Diseases Hanoi Vietnam
Huong Nguyen Thanh - National Lung Hospital Tuberculosis and Lung Diseases Hanoi Vietnam
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Hue
Pham Thi Phuong
huepham08062000@gmail.com
+undefined+undefined+undefined+undefined+undefined
Under 30
Vietnam
Case Report
CHALLENGES IN MANAGING CANDIDA AURIS CANDIDEMIA IN TUBERCULOSIS PATIENTS: A CASE REPORT FROM VIETNAM
Maximum 25 words
Abstract Content
 
 
 
 
Candida auris (C. auris) has emerged as a global multidrug-resistant threat associated with high mortality rates. In Vietnam, the rising prevalence of this pathogen poses significant challenges for tuberculosis (TB) patients, particularly due to pharmacokinetic interference with rifampicin. This report analyzes a case of C. auris candidemia in a TB patient, highlighting the complexities of drug-drug interactions and the phenotypic shift toward resistance during therapy.
A 35-year-old female patient with multisystem tuberculosis (pulmonary and spinal TB) had been receiving first-line antituberculosis therapy (2RHZE/10RHE) for two months. She was admitted for progressive spinal pain and subsequently transferred to the Intensive Care Unit (ICU) following spinal surgery. C. auriscandidemia was confirmed via blood culture, initially showing susceptibility to fluconazole and caspofungin. Despite an increased dosage of caspofungin to compensate for the enzyme-inducing interference of rifampicin, treatment failure occurred due to phenotypic switching. Transitioning the antifungal regimen to anidulafungin led to rapid clinical defervescence and microbiological clearance within 14 days of therapy.
The interaction with rifampicin leads to subtherapeutic caspofungin concentrations, serving as a critical risk factor for the emergence of antifungal recalcitrance in C. auris. Proactive microbiological reassessment and the preferential use of echinocandins with independent pharmacokinetic profiles, such as anidulafungin, are pivotal strategies for optimizing outcomes in critically ill TB patients.
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Candida auris, Echinocadin resistance, Pharmacokinetic interactions
maximum 3 keywords and no abbreviations, separated by commas
 
211